SSA
IOVA icon

Schonfeld Strategic Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-64,850
Closed -$480K – 2341
2024
Q4 		$480K Sell
64,850
-330,597
-84% -$3.06M ﹤0.01% 1425
2024
Q3 		$3.71M Buy
+395,447
New +$3.75M 0.02% 640
2024
Q2 		– Sell
-244,447
Closed -$3.62M – 2346
2024
Q1 		$3.62M Sell
244,447
-777,371
-76% -$9.05M 0.02% 761
2023
Q4 		$8.31M Buy
+1,021,818
New +$5.35M 0.06% 406
2023
Q3 		– Sell
-36,751
Closed -$259K – 2007
2023
Q2 		$259K Sell
36,751
-265,767
-88% -$1.9M ﹤0.01% 1447
2023
Q1 		$1.85M Sell
302,518
-695,582
-70% -$4.8M 0.02% 710
2022
Q4 		$6.38M Buy
998,100
+824,917
+476% +$6.44M 0.05% 413
2022
Q3 		$1.66M Buy
+173,183
New +$2M 0.01% 969
2021
Q4 		– Sell
-91,641
Closed -$2.26M – 2329
2021
Q3 		$2.26M Buy
91,641
+82,441
+896% +$1.94M 0.02% 678
2021
Q2 		$239K Sell
9,200
-20,301
-69% -$528K ﹤0.01% 1586
2021
Q1 		$935K Buy
29,501
+21,169
+254% +$877K 0.01% 923
2020
Q4 		$387K Sell
8,332
-42,637
-84% -$1.69M 0.01% 1118
2020
Q3 		$1.68M Buy
50,969
+7,610
+18% +$233K 0.03% 560
2020
Q2 		$1.19M Buy
43,359
+31,224
+257% +$1.03M 0.03% 563
2020
Q1 		$363K Sell
12,135
-214,716
-95% -$5.69M 0.02% 683
2019
Q4 		$6.28M Buy
226,851
+84,251
+59% +$1.92M 0.15% 163
2019
Q3 		$2.6M Buy
142,600
+122,800
+620% +$2.72M 0.08% 268
2019
Q2 		$485K Sell
19,800
-168,630
-89% -$2.54M 0.02% 639
2019
Q1 		$1.79M Sell
188,430
-749,870
-80% -$7.28M 0.06% 370
2018
Q4 		$8.3M Buy
+938,300
New +$9.05M 0.32% 74
2018
Q2 		– Sell
-29,541
Closed -$499K – 848
2018
Q1 		$499K Buy
+29,541
New +$447K 0.04% 477
2017
Q3 		– Sell
-34,024
Closed -$250K – 680
2017
Q2 		$250K Buy
+34,024
New +$216K 0.03% 518

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Schonfeld Strategic Advisors's IOVA Position: Q1 2025 in Review

Schonfeld Strategic Advisors sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 64,850 shares — an estimated $480K sold.

Schonfeld Strategic Advisors first reported a position in IOVA in Q2 2017 and held it in 22 quarters. The position peaked at $8.31M in Q4 2023. 301 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • Schonfeld Strategic Advisors reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 64,850 Iovance Biotherapeutics shares in Q1 2025, an estimated $480K.
  • Schonfeld Strategic Advisors first reported a position in Iovance Biotherapeutics in Q2 2017 and held it in 22 quarters.
  • Schonfeld Strategic Advisors's Iovance Biotherapeutics position peaked at $8.31M in Q4 2023.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2025, filed 15 May 2025.